Volume : 08, Issue : 12, December – 2021

Title:

43.FORMULATION AND EVALUATION OF NEVIRAPINE EXTENDED-RELEASE TABLETS

Authors :

Divya.V*, Suresh Kumar.P, Jagannath Patro.V, Sunitha. CH, Vanitha.S

Abstract :

Objective: Nevirapine (NVP) is a non nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus disease. The present study was aimed to develop generic formulation of extended release (ER) tablets of Nevirapine anhydrous (NVP) using hydrophilic polymer. Method: Nevirapine NVP(ER) tablets were prepared by direct compression. The prepared granules were evaluated for various physicochemical parameters by official procedure and compressed in tablets. The In-vitro release profile of various batches was prepared by different technologies and has been compared with the innovator product. In-vitro release profiles of NVP from ER tablets were determined using USP apparatus type II (Paddle), 50 rpm and bath temperature 37ºC. Dissolution of tablets was carried out in 900 ml of media (phosphate buffer pH 6.8). Samples were withdrawn at predetermined time intervals up to 24 hrs and analyzed using UV detector at a wavelength of 247 nm. Conclusion: Stress stability studies indicated that the formulation is stable and In-vitro release profile study showed that formulation using wet granulation technology.
Key Words: Nevirapine, Extended Release, Euudragit, Antiretroviral

Cite This Article:

Please cite this article in press V.Divya et al, Formulation And Evaluation Of Nevirapine Extended Release Tablets., Indo Am. J. P. Sci, 2021; 08(12).

Number of Downloads : 10

References:

1. Lee TWY, Robinson JR., 20th ed, 2000. Remington: the science and practice of pharmacy, 1069-70. Lippincott Williams and Wilkins, Maryland.
2. Loyd V. Allen J, Nicholas G. Popovich, Howard C. Ansel, 8th ed, 2006. Ansel: pharmaceutical dosage forms and drug delivery system, 260-275. Lippincott Williams and Wilkins, Philadelphia.
3. William Andrew, 3rd ed. Pharmaceutical Manufacturing Encyclopedia, Volume 1. Wise, Donald L., 2000. Handbook of Pharmaceutical Controlled Release Technology, 473.
4. Chein., (1982) controlled and modulated drug delivery systems, Encyclopedia of Pharmaceutical Technology, New York, Dekker :1296-1335.
5. Lee, V. H., Robinson, Sustained and Controlled Release Drug Delivery Systems, 1978 New York, NY, pp. 71-121
6. Modi *, P. D. Gaikwad, V. H. Bankar, S. P. Pawar,Sustained Release Drug Delivery System : A REVIEW, International Journal of Pharma Research and Development – Online, 2(12): 147-160
7. Aulton M.E, international student Edition, 2001. Pharmaceutics-The Science of Dosage form design, 129-191. Churchill Livingston.
8. Leon Lachman, Joseph L, Kanig., 3rd ed, 1986. The theory and practice of industrial pharmacy, 331-2, 364-8. Lea & Febiger, Philadelphia.
9. Gathe J, Andrade-Villanueva, Santiago S, Johannes R Bogner. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naïve HIV-1-infected patients. Antiviral Therapy 2011;16:759-69.
10. David Landenheim Oxford Journals > clinical infectious diseases Volume 36 Issue 9,p.p 1186-1190.
11. Crowley. M.M, Schroeder B, Frederdorf.A, Obara. S, Talarico. M, Kucera. S and Mcgrinity. J.W (2004)physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression. International Journal of Pharmaceutics. 269, 509-522.